{"id":955938,"date":"2026-04-29T08:23:58","date_gmt":"2026-04-29T12:23:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/"},"modified":"2026-04-29T08:23:58","modified_gmt":"2026-04-29T12:23:58","slug":"taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/","title":{"rendered":"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6"},"content":{"rendered":"<div class=\"mw_release\">\n<p>DALLAS, April  29, 2026  (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time.<\/p>\n<p>Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IoGvWdpBG5AcBEtYqglCzUh4Q2luWrUsEjq20CWTRg1A_6EhoV3qiw2RmheW1ZM707AGj4u0F-0Ho6tbvVL-GO2rKpVGM1TuK_EL5PL-NLbJzBtArF8OCsoPuUT4YUIQy4bUF6c4JRALC-IWnK0ZVg==\" rel=\"nofollow\" target=\"_blank\">ir.tayshagtx.com<\/a>. An archived replay of the webcast will be available on the Company\u2019s website.<\/p>\n<p>\n        <strong>About Taysha Gene Therapies<\/strong><br \/>\n        <br \/>Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company\u2019s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jrc-p29wSC2zIcBdnPwK53MvWeXw3QHYwr1SPOjRzBtAKQLcbSEcW_tm9pso9_EB3yW75zdyw4zH7QN01MiBOi-IfrZb988rNYiIY6W1XSk=\" rel=\"nofollow\" target=\"_blank\">www.tayshagtx.com<\/a>.<\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Hayleigh Collins<br \/>Senior Director, Corporate Communications and Investor Relations<br \/>Taysha Gene Therapies, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7VnxybVpg1d9apo3wgme33DCLizuSGTQQKHmSSnt0wEuClmTG01eKXOjoIIIHTWEdJ4Ln3UhjlVNS3bG2TO4ClU_y02UJtQBFcFN5S3rwNE=\" rel=\"nofollow\" target=\"_blank\">hcollins@tayshagtx.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Carolyn Hawley<br \/>Inizio Evoke<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bsMB9E7bqiwMj9J5t7dodrzSiae6HR6dNJ6uwSdTIgRdzehUc_LUYln9cLN0WxdxFi_3zZaIDGU_X_aJo-BkqF8o_ppZ-9nDst-qs9GVC5PBE4jODR4BAuFij1dcv_c1\" rel=\"nofollow\" target=\"_blank\">Carolyn.hawley@inizioevoke.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWViMzNmNWItMmJmNC00N2YwLThlZTEtMmMxMGRjZWIzZDBkLTEyMTM5NjYtMjAyNi0wNC0yOS1lbg==\/tiny\/Taysha-Gene-Therapies-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DALLAS, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha\u2019s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company\u2019s website. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955938","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DALLAS, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha\u2019s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company\u2019s website. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a &hellip; Continue reading &quot;Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-29T12:23:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6\",\"datePublished\":\"2026-04-29T12:23:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/\"},\"wordCount\":284,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/\",\"name\":\"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=\",\"datePublished\":\"2026-04-29T12:23:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/","og_locale":"en_US","og_type":"article","og_title":"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Market Newsdesk","og_description":"DALLAS, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha\u2019s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company\u2019s website. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a &hellip; Continue reading \"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-29T12:23:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6","datePublished":"2026-04-29T12:23:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/"},"wordCount":284,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/","name":"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=","datePublished":"2026-04-29T12:23:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjEyMSM3NTUyOTc5IzIyMDI0MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955938"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955938\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}